/ /

Professor Anat Loewenstein
Dexamethasone for DME shows stronger results compared with sham group
In this article Dr Anat Lowenstein explains that the benefits of treatment with a dexamethasone intravitreal implant for DME were observed across a variety of demographic characteristics.
The future of anti-VEGF
This article provides a brief overview of the outcomes of a webex meeting hosted by Novartis at SOE 2013 in Copenhagen, Denmark.


View Results